Scandinavian ChemoTech AB is carrying out another directed new share issue and will receive approximately MSEK 2.5
Scandinavian ChemoTech AB (publ) (“ChemoTech” or “the Company”) hereby announces that the Company has carried out a directed new share issue which will provide the Company with approximately MSEK 2.5. The capital injection will be used to repay loans.The Board of ChemoTech has, with the support of authorisation from the Annual General Meeting on May 24, 2021, decided on a directed new issue of 121,417 Series B shares at the same terms and conditions as the previously closed directed share issue which provided the Company with approximately MSEK 18. Thus, the subscription price amounts to